Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Conformis Inc.

$CFMS
Industrial Specialties
Health Care
Get the next $CFMS alert in real time by email
SC 13G 1 cfms222.txt SCHEDULE 13G Amendment No. Name of Issuer: Conformis Inc. Title of Class of Securities: Common Stock CUSIP Number: 20717E101 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 18,252,244 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 18,252,244 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 18,252,244 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 9.8% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Conformis Inc. Item l(b): Address of Issuer: 600 Technology Drive, Billerica, MA 01821 Item 2(a): Name of Person Filing: Wasatch Advisors, Inc. Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 20717E101 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 18,252,244 Item 4(b): Percent of Class Owned: 9.8% Item 4(c)(i): Sole Voting Power: 18,252,244 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 18,252,244 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [ ] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2021. Date: 02/11/22 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO
Get the next $CFMS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CFMS

DatePrice TargetRatingAnalyst
11/4/2021$2.50 → $2.00Outperform
Oppenheimer
9/22/2021$3.00 → $2.50Outperform
Oppenheimer
More analyst ratings

$CFMS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • restor3d Completes Acquisition of Conformis

    DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

    $CFMS
    Industrial Specialties
    Health Care

  • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

    BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

    $CFMS
    Industrial Specialties
    Health Care

  • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

    BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

    $CFMS
    Industrial Specialties
    Health Care

$CFMS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CFMS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CFMS
 SEC Filings

See more

$CFMS
 Leadership Updates

Live Leadership Updates

See more

  • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

    BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

    BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

    BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

    $CFMS
    Industrial Specialties
    Health Care

$CFMS
 Financials

Live finance-specific insights

See more

  • Conformis Reports First Quarter 2023 Financial Results

    BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

    BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

    BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

    $CFMS
    Industrial Specialties
    Health Care

$CFMS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more